The Advisory Board has a collective 125 years of experience in technology development, corporate growth management, legal, financing, operations, and business development ranging from large fortune 500 companies, leading law firms, successful financial management firms, and to technology start-ups that realized significant exits.
"We are growing quickly, and we've reached a stage that merits a robust Advisory Board accomplished enough to support this growth," stated Gannon Giguiere, Eventure Interacvtive's CEO and Chair of the Advisory Board. Mr. Giguiere went on to say, "We are pleased to have assembled such a talented and noteworthy group of executives who we believe bring the depth of experience and breadth of relationships that the Company will be able to tap for insights and advice as we move through this high growth phase. Having this Advisory Board in place ensures the Company will fully execute to, as well as capitalize on, current and future market opportunities."
Eventure's Advisory Board consists of Darren Reinig, Founding Partner of Delphi Private Advisors; Vinay Jatwani, Founder and CEO of Jigsaw Partners; Bruce Hallett and Bob Holmen, co-Managing Directors of Miramar Venture Partners; Patrick Whelan, President of Declan, LTD.; Allan Knepper, COO of Emerging Market Access Group; and Harrison Group, a leader in growth advisory consultation.
What They Do: Eventure truly redefines how one organizes life's most memorable moments. For the first time ever, there's a Social Calendar to use.
Venaxis, Inc. (Nasdaq: APPY), $2.71. Today announced positive top-line results from its pivotal U.S. study. The APPY1 Test performed well, with sensitivity and negative predictive value results that exceeded those from the previous pilot study. The company believes these pivotal results are sufficient for potential FDA clearance and expects to finalize its 510(k) submission and file with the FDA in the next few weeks.
In the measure of negative predictive value (NPV), which is the primary metric for the APPY1 Test, the results were 97.3%, with a lower 95% confidence limit of 95.5%. Additionally, the APPY1 Test performed with sensitivity of 96.9% (lower 95% confidence limit of 94.9%). Specificity for APPY1 was 37.8% (lower 95% confidence limit of 35.3%), which is believed to be adequate for an adjunctive, negative predictive test such as the APPY1 Test. Overall prevalence of appendicitis was 25%, which was also in line with expectations and the medical literature.
What They Do: Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis.
magicJack VocalTec (Nasdaq: CALL) $17.53. Announced Wednesday after market close financial results for the fourth quarter and full year ended December 31, 2013.
Net revenues: Total net revenues were $38.2 million. Net revenues from the sales of magicJack devices were $15.1 million and access rights renewal revenues were $14.8 million, an increase of 23% on a year-over-year basis, and accounted for 39% of total net revenues. Prepaid minute revenues were $3.0 million and access and wholesale charges were $1.8 million during the quarter. Other revenue contributed the remaining $3.6 million of total net revenues during the fourth quarter of 2013.
Net income: GAAP net income for the fourth quarter of 2013 was $45.3 million, compared to $22.3 million for the same period last year. GAAP diluted income per share for the fourth quarter was $2.50, based on 18.1 million weighted-average diluted shares outstanding, compared to $1.17, based on 19.0 million weighted-average diluted shares outstanding, for the same period last year.
What They Do: majicJack is the inventor of the magicJack and the industry's original VoIP (voice over IP) service in 2008, is a leading cloud communications company.
Superconductor Technologies (Nasdaq: SCON) $3.28. Today announced it has recently entered into a non-exclusive license agreement with an international company for a wireless technology patent previously developed by STI. In consideration for the use of the patent, STI will receive cost savings on support equipment for its Conductus HTS wire program. The equipment will enhance STI's capabilities as capacity increases to commercial volumes.
"Our intellectual property (IP) position is a valuable company asset," said Jeff Quiram, STI's President and CEO. "With our latest licensing agreement, we have utilized IP developed for our legacy wireless business as a financial resource to support the commercial production of Conductus(R)
What They Do: Superconductor Technologies has been a world leader in HTS materials since 1987, developing more than 100 patents as well as proprietary trade secrets and manufacturing expertise.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview has been compensated six thousand seven hundred fifty dollars by Eventure Interactive and expects to receive an additional six thousand seven hundred fifty dollars in the future for its efforts with regards to Eventure Interactive.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play. To sign up visit http://www.smallcapreview.com/